A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 28-DAY STUDY OF DEN

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to investigate the safety and effectiveness of two dose strengths of INS37217, 20 mg and 60 mg, compared to placebo. Placebo is a sterile saline (salt water) solution. The study drug (INS37217 or placebo) will be administered via a nebulizer three times per day for up to 28 days to patients with CF lung disease. It is hoped that this study will help select the appropriate dose for further studies of INS37217 in cystic fibrosis patients.